CTLA4 and hypophysitis: The rate of hypophysitis is 5.6% for ipilimumab (CTLA4-inhibitor), 0.5% for nivolumab (PD1-inhibitor), 1.1% for pembrolizumab (PD1-inhibitor) and 8.8–10% for the combination [92].